IDEXX Sales Rise 10% as Margin Outlook Slips: Rapid Earnings Reaction
Key Points
IDEXX grew third-quarter revenue 10% to about $1.21 billion, led by an 11% gain in recurring diagnostics sales to vets.
The higher 2026 profit forecast doesn’t come from testing demand.
- 10 stocks we like better than Idexx Laboratories ›
IDEXX Laboratories (NASDAQ:IDXX) grew third-quarter revenue 10% to about $1.21 billion, led by an 11% gain in recurring diagnostics sales to vets. Shares rose about 16% in early trading on Monday. Testing demand is doing the work, but the higher 2026 profit forecast doesn't come from it. IDEXX trimmed its margin outlook, so the earnings raise rests on taxes, interest costs, and buybacks.
Key Numbers
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
- Revenue: $1.21 billion, up 10% from $1.11 billion.
- CAG Diagnostics recurring revenue: $967 million, up 11%.
- Operating margin: 33.1%, up from 32.1%.
- Diluted EPS: $4.01, up 18% from $3.40.
What It Means
VetLab consumables, the supplies vets use to run tests on IDEXX's in-clinic analyzers, rose 14% and made up more than half of the recurring gain. That's the razor-and-blade model: each new analyzer turns into years of test sales. It's also why flat instrument revenue isn't a worry. Placements matter more than the price paid for the box.
IDEXX raised its revenue range but cut its operating margin outlook, which leaves full-year operating profit about where the old midpoint had it. The $0.25 lift to the EPS forecast leans instead on a lower tax rate, less interest expense, and fewer shares. Those help this year but don't compound like test volume.
The margin cut also points at the fourth quarter. Margin gains through nine months already top the new full-year target, which implies little or no improvement in the last quarter as IDEXX absorbs costs from its CoVet software deal.
What to Watch Next
Watch fourth-quarter operating margin against last year's, since the guidance implies it barely moves. Also watch rapid assay products, where testing volumes fell this quarter and price alone kept sales growing.
Should you buy stock in Idexx Laboratories right now?
Before you buy stock in Idexx Laboratories, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Idexx Laboratories wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $334,793!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,257,420!*
Now, it’s worth noting Stock Advisor’s total average return is 874% — a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 2, 2026.
David Kretzmann has positions in Idexx Laboratories. The Motley Fool has positions in and recommends Idexx Laboratories. The Motley Fool has a disclosure policy.
Recommended Articles
